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Mutations in the CNGB3 gene account for >50% of all known cases of achromatopsia. Although of early
onset, its stationary character and the potential for rapid assessment of restoration of retinal function follow-
ing therapy renders achromatopsia a very attractive candidate for gene therapy. Here we tested the efficacy of
an rAAV2/8 vector containing a human cone arrestin promoter and a human CNGB3 cDNA in CNGB3 deficient
mice. Following subretinal delivery of the vector, CNGB3 was detected in both M- and S-cones and resulted in
increased levels of CNGA3, increased cone density and survival, improved cone outer segment structure and
normal subcellular compartmentalization of cone opsins. Therapy also resulted in long-term improvement of
retinal function, with restoration of cone ERG amplitudes of up to 90% of wild-type and a significant improve-
ment in visual acuity. Remarkably, successful restoration of cone function was observed even when treat-
ment was initiated at 6 months of age; however, restoration of normal visual acuity was only possible in
younger animals (e.g. 2–4 weeks old). This study represents achievement of the most substantial restoration
of visual function reported to date in an animal model of achromatopsia using a human gene construct, which
has the potential to be utilized in clinical trials.
INTRODUCTION
Complete congenital achromatopsia is a devastating hereditary
visual disorder, which is associated with a deficient cone-
mediated electroretinogram (ERG) response, color blindness,
visual acuity loss, pendular nystagmus, extreme light sensi-
tivity and daytime blindness (1–3). Mutations in four different
genes have been identified so far as responsible for causing
achromatopsia: the cone alpha transducin subunit (GNAT2),
the alpha-prime subunit of cone phosphodiesterase (PDE6C)
and the alpha (A) and beta (B) subunits of the cone cyclic
nucleotide-gated (CNG) channel (CNGA3 and CNGB3,
respectively) (3). Among these genes, mutations in CNGA3
and CNGB3 account for 25 and 50%, respectively, of all
achromatopsia cases, while GNAT2 and PDE6C together
only affect 2% of achromatopsia patients (1,3–5). Nystag-
mus and sensitivity to bright light develop within a few
weeks after birth and although these can improve slightly
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over time, poor visual acuity (20/200 or less) remains stable
throughout life (1–3). Hence, achromatopsia is a severe visual
impairment and yet a relatively stationary condition. These
factors coupled with the potential for rapid assessment of treat-
ment efficacy through evaluation of cone function and visual
acuity renders achromatopsia an ideal candidate for gene therapy.
Rod and cone photoreceptor CNG channels are localized to
the plasma membrane of the outer segment and play a pivotal
role in phototransduction (6,7). Structurally, CNG channels
belong to the superfamily of voltage-gated ion channels and
comprise two structurally related subunit types, the A and B
subunits: CNGA1/B1 in rods and CNGA3/B3 in cones. Heter-
ologous expression studies have shown that the A subunits
form the ion-conducting unit, while the B subunits function
as modulators (8,9).
Mutations in CNGA3 and CNGB3 have been linked to achro-
matopsia, progressive cone dystrophy and some maculopathies;
with mutations in CNGB3 alone accounting for .50% of all
known cases of achromatopsia (5,10–12). Among the
mutations in the CNGB3 gene, the frame-shift mutation
Thr383fsX has the highest frequency, accounting for .80%
of all CNGB3 mutant alleles (2,5,13,14). This mutation trun-
cates the pore-forming region and the cytoplasmic C-terminal
domain, leading to a null allele. Hence, gene-supplementation
therapy would be an appropriate approach to treat the majority
of the patients with CNGB3 mutations.
As for many other types of hereditary retinal disorders,
there are currently no effective treatments for cone defects
resulting from CNG channel deficiency. Among a variety of
novel therapeutic strategies that are under investigation, gene
therapy has been shown to be most promising. Indeed, AAV
(adeno-associated virus)-mediated gene therapy for inherited
retinal disorders has been successful in a variety of animal
models, including rodent and canine models of Leber congeni-
tal amaurosis (LCA) (15–20), the CNGA3 and GNAT2
deficiency mouse models (21,22) and canine models of
CNGB3 mutation/deficiency (23). Gene therapy even has
been shown to be capable of generating an additional cone
class in dichromate primates (24). Moreover, three indepen-
dent clinical trials of AAV-mediated gene therapy for LCA
caused by RPE65 deficiency have reported clinical benefit
(25–27), leading the way for future trials of gene therapy
for other forms of inherited retinal dystrophies.
Over the last four years, there has been considerable pro-
gress in developing gene therapy for achromatopsia using
various animal models. Previous studies have demonstrated
restoration of cone function and improvements in photopic
vision in a canine model of CNGB3 deficiency and in
Gnat22/2 and Cnga32/2 mouse models following AAV-
mediated gene therapy (21–23). Both the Cnga32/2 and the
Gnat22/2 mouse model studies used a mouse cDNA trans-
gene that could in part explain the almost wild-type levels
of photopic ERG recovery observed in Gnat22/2 mice after
treatment (22). The same, however, was not seen in the
treated Cnga32/2 mice, which only displayed ERG recovery
of 30% of wild-type levels (21). The least improvement in
function was observed in the canine CNGB32/2 model,
where only 10% ERG recovery was seen after treatment
(23). This possibly may have been due to the use of the
human CNGB3 transgene; alternatively, the results may be
attributed to the relatively modest extent (30% of total) of
retinal area transduced in that study (23). Due to the presence
of different cone types in the human retina, the choice of pro-
moter is of crucial importance when considering gene therapy
for achromatopsia. In the previously reported Gnat22/2 and
CNGB32/2 gene therapy studies (22,23), PR2.1 (a 2 kb
human M/L cone opsin promoter) was used to drive transgene
expression. Although PR2.1 is a robust promoter that mediates
high levels of expression, it is active only in M/L-cones, not
S-cones (28). The Cnga32/2 study used a 0.5 kb fragment
of the mouse blue opsin promoter that is active in S-cones
but is only active in a subset of M-cones (29).
We have previously shown that the phenotype of Cngb32/2
mice reflects the symptoms of patients carrying CNGB3
mutations, namely impaired cone function and early onset,
slow progression of cone degeneration (30,31). This similarity
makes the Cngb32/2 mouse line a valuable model to
explore therapeutic interventions for the treatment of
CNGB3-associated cone diseases. Taking into account previous
gene therapy studies in other models of achromatopsia, our aim
was to use this novel model of CNGB3 deficiency to optimize a
treatment for the most common form of achromatopsia. We
selected a recombinant AAV2/8 vector to deliver a human
cDNA transgene driven by a strong human promoter that is
active in both S- and M-cones. Congenital achromatopsia has
an early onset, but remains mostly stationary in humans,
which opens the question as to whether there is a window of
time for effective treatment or, due to the stationary aspect of
the disease treatment, if outcome is independent of the age at
which a patient is treated.
RESULTS
Subretinal injection of an AAV2/8 vector containing a
human cone arrestin promoter results in cone-specific
transgenic expression in Cngb32/2 mice
We constructed a recombinant AAV2/8 viral vector containing
a 0.4 kb fragment of the human cone arrestin promoter
(hCAR) and the human CNGB3 cDNA (rAAV2/
8_hCAR_hCNGB3). The vector was injected subretinally
into Cngb32/2 mice at post-natal day 15 (P15). Eyes were iso-
lated at 30 days post-injection (PI) and expression of CNGB3
was evaluated by immunohistochemistry. As shown in
Figure 1, CNGB3 immunoreactivity was detected in the
outer segments in retinal sections prepared from eyes that
had received vector, but not in the uninjected controls. Cone-
specific CNGB3 transgene expression was demonstrated in
both M- and S-cones by co-labeling with the antibodies
against M-opsin and S-opsin, respectively (Fig. 1).
Increased levels of CNGA3 in Cngb32/2 mice following
CNGB3 gene delivery
Heterologous expression studies suggest that CNGA3 is the
ion-conducting subunit, while CNGB3 functions as a modu-
lator (9,32–34). These studies are supported by the obser-
vation that Cnga32/2 mice show a complete loss of cone
response, while Cngb32/2 mice have a residual cone function
(30,31,35). We have shown previously that expression of
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Cnga3 is down-regulated in Cngb32/2 mice making it likely
that the residual cone function in Cngb32/2 mice is a function
of the remaining CNGA3 homomeric channels and that
reduced levels of CNGA3 are responsible for the cone
defects in CNGB3 deficiency (31). Therefore, we examined
expression of Cnga3 in the treated eyes to determine
whether supplementation of CNGB3 improves the levels of
expression of Cnga3. Eye sections, retinal membrane protein
preparations and retinal total RNA preparations were used
for analyses of Cnga3 expression. Figure 2A shows improved
levels of CNGA3 expression by immunohistochemistry in
retinal sections from treated Cngb32/2 mice compared with
untreated controls and wild-type mice. Figure 2B shows
western blot detection of CNGA3 in the treated Cngb32/2
mice compared with the untreated controls, wild-type and
Cngb3+/2 mice. Densitometric quantitative analysis
(Fig. 2C) shows that the level of CNGA3 in the treated eyes
(densitometric units: 25.2 + 4.3) was increased significantly
(P , 0.05) compared with the un-injected controls (densito-
metric units: 9.6 + 2.1), and was comparable to that seen
Figure 1. Subretinal injection of AAV2/8 vector containing human cone arrestin promoter results in cone-specific transgenic expression in Cngb32/2 mice.
Injections were performed at P15 and eyes were collected at 30 days PI to analyze expression of CNGB3. Immunohistochemical detection of CNGB3 expression
in the treated (a, b, c) and untreated (d, e, f) Cngb32/2 mice. Retinal cross-sections were immunolabeled for CNGB3 (green), S-opsin (red), M-opsin (red) with a
nuclear counterstain (DAPI, blue). c′ and f′ are higher magnification images of treated and untreated overlay. Shown are representative images of the analyses
from 4 to 6 mice/group. OS, outer segment; ONL, outer nuclear layer; and INL, inner nuclear layer. Scale bars ¼ 50 mm.
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in the Cngb3+/2 mice (densitometric units: 25.0 + 1.0).
Figure 2D shows significant increased expression of Cnga3
mRNA as analyzed by qRT–PCR (P , 0.05). Thus, these
results demonstrate that delivery of the CNGB3 transgene
increases the levels of Cnga3 in Cngb32/2 mice by increasing
the expression of Cnga3.
Improved cone ERG responses in Cngb32/2 mice
following gene therapy
In order to determine whether gene supplementation leads to
long-term restoration of cone function and if there was an
optimal age window for effective treatment, vector was
injected at P6, 15, 30, 90 and 180. ERG recordings were
then performed at monthly intervals, starting at 30 days PI.
Figure 3 shows a comparison between representative ERG
traces from treated, untreated and wild-type recordings in
animals treated at P30 and assessed 120 days PI. We
observed substantial rescue of photopic flash and flicker
responses in treated animals, while scotopic traces remained
unchanged. Averaged ERG recordings measured at 3–4
months PI for all age groups are shown in Figure 4. There
was significant improvement in function between treated
and untreated eyes in all age groups (P , 0.05). However,
it is evident from the results that an ideal window for treat-
ment is present around P15–30 and thus the group injected
at P30 was selected to evaluate the long-term efficacy of
treatment. Figure 5 shows that the photopic ERG response
in injected eyes was restored to near wild-type levels in
this group and persisted for up to 270 days PI (the longest
time point examined here). Moreover, we were able to
observe a consistent long-term effect of treatment in all age-
treated groups up to 180 days PI (Fig. 6). These experiments
show that treatment performed at P15 and P30 achieves a
near complete ERG restoration (.90% of wild-type level),
while treatment performed at P90 and P180 resulted in func-
tional rescue at 70–80% and 60–70% of wild-type levels,
respectively. The group showing the smallest rescue was
the group treated at P6, where visual function only
reached 55% of wild-type levels. This could be explained
by the increased amount of retinal damage observed after
injection in the P6 animals, most likely caused by the
small eye size and increased surgical trauma (data not
shown), but the possibility of low vector transduction and,
consequently, low CNGB3 expression levels in these
younger treated animals can also not be excluded.
Improved visual acuity in Cngb32/2 mice following gene
therapy
Untreated Cngb32/2 mice have already been shown to have
decreased visual acuity as assessed by observing their optomo-
tor responses under photopic conditions (31). As shown
earlier, ERG responses demonstrated that functional
Figure 2. Increased levels of CNGA3 in Cngb32/2 mice following hCNGB3 gene delivery. Viral injections were performed at P15 and eyes were collected at 30
days PI to check for expression of CNGA3. (A) Immunohistochemical detection of CNGA3 in the treated and untreated Cngb32/2 eyes. Shown are representa-
tive images of the analyses from 4 to 6 mice/group. OS, outer segment; ONL, outer nuclear layer; and INL, inner nuclear layer. Scale bars ¼ 50 mm. (B) Western
blot to detect CNGA3 in eyes from wild-type, Cngb3+/2 and treated and untreated Cngb32/2 mice. Retinal membrane preparations were resolved by 10%
SDS–PAGE, followed by immunoblotting using a polyclonal anti-CNGA3 antibody. (C) Quantification of western blot analysis in densitometric units.
(D) qRT–PCR detection of Cnga3 mRNA expression. Total RNA was prepared and used in the qRT–PCR assays with primers designed for mouse Cnga3.
Values are means+SEM (n ¼ 5–7 mice/group). Unpaired Student’s t-test was used for determination of the significance between treated and untreated
eyes (∗P , 0.05).
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improvement at the retinal level was possible in both P30 and
P180 treated animals, but whether both groups would have the
necessary plasticity to restore appropriate behavioral
responses was unclear. We therefore examined whether sup-
plementation of the CNGB3 transgene could improve visual
acuity. Two groups of treated Cngb32/2 mice (injected at
P30 and P180) were tested for their optomotor response
(Fig. 7A and B) to examine whether age at treatment had
any impact on visual function. As shown in Figure 7C,
untreated animals have a significantly lower visual acuity
than wild-type (untreated: 0.410+SD cycles/degree; n ¼
11; wild-type: 0.525+SD cycles/degree; n ¼ 6; P, 0.01),
consistent with a prior report (31). However, after treatment,
visual acuity in the P30-treated animals was restored to a
similar level (0.520+SD cycles/degree; n ¼ 11) as that
observed in wild-type animals (0.525+SD cycles/degree;
n ¼ 6; P ¼ 0.83) In contrast, we observed no significant
difference in visual acuity between the treated and untreated
eyes in the P180 group (wild-type: 0.510+SD cycles/
degree; treated: 0.438+SD cycles/degree; untreated:
0.410+SD cycles/degree; n ¼ 6; P ¼ 0.58), indicating that
treatment received at an older age is less capable of restoring
visual acuity. There was no statistical difference in contrast
sensitivity between wild-type and treated and untreated
Cngb32/2 eyes for the either the P30 or P180 groups
(Fig. 7C; P . 0.27). Therefore, the results presented here
show that visual acuity can be restored in Cngb32/2 mice
by administration of rAAV2/8_hCAR_hCNGB3, but there is
an inverse correlation between the age of treatment and the
degree of improvement in visual function (i.e. the older the
age of treatment initiation, the worse the visual function
outcome).
Gene therapy improves cone survival in Cngb32/2 mice
We have previously shown that cones degenerate in
Cngb32/2 mice (31). This was evidenced by decreased cone
density and decreased expression of cone-specific proteins
including cone opsin, cone transducin (GNAT2) and cone
arrestin (CAR). In this study, we examined whether adminis-
tration of rAAV2/8_hCAR_hCNGB3 improves cone survival.
As cone degeneration in Cngb32/2 mice occurs early, with
decreased cone density already occurring at P30 (30,31),
we administered vector at P15 and evaluated cone survival
8 weeks PI. We found that cone density, as evaluated by
peanut agglutinin (PNA) labeling, in the treated eyes (470+
17/mm2) was significantly increased (P , 0.01), compared
with the untreated eyes (390+ 12/mm2 - Fig. 8A, upper
panels). In addition, immunofluoresence labeling showed
that M-opsin and S-opsin were more abundant in treated
(442+ 7/mm2 and 472+ 13/mm2, respectively) compared
Figure 4. Restoration of cone-mediated ERG in Cngb32/2 mice treated at
different ages. Data are represented as means+SEM of photopic b-wave
ERG recordings done at.10 cd.s/m2 measured at ca 3–4 months post-injection.
Treated and untreated n for each group was as follows: P6 ¼ 6; P15 ¼ 6;
P30 ¼ 11; P90 ¼ 9; P180 ¼ 6. Wild-type measurements were from 5 to 7
animals. Paired Student’s t-test was used to determine significance between
treated and untreated eyes in all age groups; all showed significance
(P-values as follows: P6, P ¼ 0.045; P15, P ¼ 0.0017; P30, P ¼ 9 × 1026;
P90, P ¼ 0.0006; P180, P ¼ 0.0024. Unpaired Student’s t-test was used to
determine significance between treated and wild-type eyes; only the P6 and
P180 groups were significantly different (∗P ¼ 0.0017; ∗∗P ¼ 0.0259).
Figure 3. Representative ERG traces from Cngb32/2 mice following gene
therapy. Wild-type and untreated traces are shown in parallel for comparison.
Representative traces shown are from the P30 injected group. Scotopic
measurements shown here are from 0.007 cd.s/m2 intensity. Photopic flash
recordings shown are from 10 cd.s/m2 intensity and flicker recordings are of
varying frequencies on a 20 cd.s/m2 background light.
Figure 5. Long-term restoration of cone-mediated ERG following gene
therapy. Photopic flash ERGs were recorded at 10 cd.s/m2. For each time
point, data represent the mean+SEM of measurements from 9–11 eyes for
treated and untreated mice; six mice were used for age-matched wild-type con-
trols. Two-way ANOVA was used to determine significance. Treated and
untreated groups were statistically significant at all time points (P , 0.001),
while treated and wild-type groups were not significant at any time point
(P . 0.05).
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with untreated eyes (367+ 10/mm2 and 314+ 10/mm2,
respectively; Fig. 8A, middle and lower panels). Improved
expression of cone-specific proteins, including cone opsin,
GNAT2 and CAR was also shown by Western blotting
(Fig. 8B).
Reduced cone opsin mis-localization in Cngb32/2 mice
following treatment
Mis-localization of cone opsins to the inner segments, outer
nuclear layer (ONL) and outer plexiform layer (OPL) has
been observed in Cngb32/2 mice (30). We therefore exam-
ined whether expression of the CNGB3 transgene could
improve outer segment localization of cone opsin. As this phe-
notype was more profound in young mice, we performed
injections at P6 and examined localization of cone opsin at
P16. Figure 9A shows M-opsin labeling in the treated eyes,
compared with untreated eyes. The extent of mis-localization
of cone opsin in the ONL and OPL was substantially
reduced and cone-opsin labeling was correctly localized to
the outer segments in treated eyes and indistinguishable
from wild-type controls. Figure 9B shows the quantitative
results of the fluorescence intensities of M-opsin labeling in
the outer segment, ONL and OPL of the treated mice
compared with that in the untreated controls. The fluorescence
intensities in ONL and OPL in treated eyes (1.0 + 0.21
and 3.3 + 0.74, respectively) were significantly reduced
(P , 0.01) compared with the untreated eyes (2.9 + 0.38
and 11.9 + 1.3, respectively).
Preservation of cone structure in treated Cngb32/2 mice
Ultrastructural defects in cone outer segment (COS) structure
in Cngb32/2 mice has been shown previously (31). While
CNGB3 deficiency does not prevent the formation of ultra-
structurally normal COSs, it contributes to the subsequent
inability of cone cells to maintain normal structural integrity.
We examined whether administration of rAAV2/
8_hCAR_hCNGB3 can promote the preservation of normal
COS structure in Cngb32/2 mice by using transmission elec-
tron microscopy (EM). The treatment was performed at P15
and eyes were collected at 60 days PI and processed for
EM analysis. Supplementation with the CNGB3 transgene
effectively preserves COS structure in Cngb32/2 mice com-
pared with the untreated Cngb32/2 mouse controls. As
shown in Figure 10, Cngb32/2 cones exhibited ultrastructural
abnormalities in their outer segments, including disorganiz-
ation, misalignment, discontinuities and frank disintegration
of disc structure, as well as apparent trapping of cytoplasmic
or extracellular matrix material within the space delineated by
the COS plasma membrane that formerly housed the intact
COS (Fig. 10A and C). In contrast, COS in transgene-treated
mice were ultrastructurally normal, well-aligned and intact
(Fig. 10B and D). It is important to note that the rod outer
Figure 6. Linear regression analysis of the ratios of b-wave amplitudes from treated/untreated eyes over time. Each panel shows the regression slope for each age
group. Each point represents the ratio of b-wave amplitude (10 cd.s/m2) between treated and untreated eyes (AT/AU) for an individual animal at each time point.
For all treatment groups the therapeutic effect was maintained over time. The ratio between the photopic ERG response of treated and untreated mice is shown up
to 180 days post-injection in all groups, apart from those treated at P90 as these animals were sacrificed at 90 days post-injection to provide samples for the
experiments evaluating cone survival and degeneration. n numbers varied slightly between groups and time points due to failed ERGs on individual mice on
particular days. Although statistical analysis suggests a slight improvement in the P6 and P180 groups, we do not consider these differences biologically relevant
(P ¼ 0.016 and P ¼ 0.027, respectively).
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segments in both treated and untreated mice were structurally
normal; this is expected, since the gene deficiency is cone-
specific.
DISCUSSION
Effective gene therapy for achromatopsia requires efficient
transgene expression in both S- and M-cones. Here, we
describe the first gene therapy for cone-related dystrophies
which uses the human CAR promoter to drive transgene
expression in cones ubiquitously. Although Michalakis et al.
(21) were able to show transgene expression (with an S-cone
promoter) in both S- and M-cones in the transduced
Cnga32/2 mouse retina, this could be explained by the high
level of S- and M-opsin co-expression in mouse photo-
receptors (36). While the S-opsin promoter induced expression
in both M- and S-cones in the mouse retina, it may not have
the same effect in humans. Therefore, due to the restricted
expression in different subsets of cones and possibly bipolar
cells (37), neither the PR2.1 nor any blue opsin promoters
are as suitable for use in a clinical setting for achromatopsia
gene therapy as the CAR promoter which offers specific and
robust transgene expression in all types of mouse cones.
Komaromy et al. (23), however, have previously reported
low levels of cone arrestin in the S-cones of dogs and it there-
fore remains to be seen whether this hCAR is active in all
cones in the dog retina and more importantly in all human
cone subtypes.
The AAV serotype is another factor that contributes to an
efficient transgene delivery. Although the rAAV5 serotype
has been shown to transduce a significantly greater number
of photoreceptor cells compared with rAAV2 (38), the
rAAV8 serotype has an even higher transduction efficiency
and has been shown to transduce a higher number of cones
than rAAV5 (38–40), potentially making it the ideal choice
of vector for achromatopsia gene therapy. Since both the pro-
moter and transgene are of human origin, the construct used in
this study would be very suitable for use in patients with
achromatopsia.
This study has shown that supplementation of the CNGB3
transgene also can increase expression of CNGA3 in
Figure 7. Improved visual acuity in Cngb32/2 mice following gene therapy. Visual acuity and contrast sensitivity measurements taken at 60 days post-injection
from the Cngb32/2 animals treated at P30 and P180. (A) Schematic showing the Optomotry# set-up. The mouse sits on a platform surrounded by four computer
screens, which project a rotating sinusoidal striped grating. Involuntary reflex head-tracking responses are driven by the left (clockwise rotations, black arrow)
and right (counter-clockwise rotations, white arrow) eyes, respectively. (B) The set up permits two measures of visual function, contrast sensitivity and visual
acuity. (C) Visual acuity is restored to wild-type levels in the eyes treated at P30 (top left panel) but not in the eyes treated at P180 (top right panel). Response of
the untreated eye remained at 85–80% of wild-type level. Contrast sensitivity (lower panels) remained the same between treated, untreated and wild-type eyes
for both P30 and P180 treated animals. Data are representative as means+SD of measurements of 11 and 6 eyes for the treated and untreated groups for P30 and
P180, respectively, and 12 eyes for wild-type controls. Paired Student’s t-test was used to determine significance (P, 0.001).
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Cngb32/2 mice. CNGA3 is known as the ion-conducting
subunit, while CNGB3 is a modulator. In heterologous
expression systems, a CNGA3 homomeric channel is fully
functional (9,32) and co-expression of CNGB3 with CNGA3
forms heteromeric channels that display a number of proper-
ties typical of native CNG channels (9,34). Although
CNGB3 shares a common topology with CNGA3 and pos-
sesses a pore-forming region, expression of this subunit
alone does not form a functional channel (9,32). Taken
together, the findings that deficiency of CNGA3 leads to com-
plete loss of cone response (35), while Cngb32/2 mice show a
residual cone response (31), plus the work showing interaction
between CNGA3 and CNGB3 in mouse retina (41), support
the cell culture findings. We speculate that the residual cone
function in Cngb32/2 mice is likely a function of the remain-
ing CNGA3. We have shown a reduced expression of CNGA3
at both the protein and mRNA level in Cngb32/2 mice (31);
interestingly, a down-regulation of Cngb3 also was observed
in Cnga32/2 mice (42). The mechanism by which the two
types of the channel subunits inter-regulate each other
remains to be identified. Nevertheless, this study showed
that supplementation of the CNGB3 transgene improved
expression of the CNGA3 subunit and that the expressed
CNGA3 was able to traffic correctly into the outer segments.
Thus, the functional rescue in the treated eyes is likely associ-
ated with the restoration of the heteromeric channels and an
improved expression of CNGA3. Indeed, without sufficient
levels of CNGA3, it is unlikely that there would be enough
functional channel complexes to sustain cone
phototransduction. It is worth noting that the levels of
CNGA3 in treated animals did not reach that of wild-type
animals (about half the wild-type level, and equivalent to the
level of Cngb3+/2 mice, based on the immunoblotting
results). The reason for why the CNGA3 level in treated
animals did not reach that of wild-type animals is unknown.
It might be related to the expression levels of CNGB3 trans-
gene or due to a difference between human and mouse
CNGB3 subunit. In the wild-type cones there are mouse
CNGB3 and CNGA3, while in the treated Cngb32/2 cones
there are human CNGB3 and mouse CNGA3. The inter-
subunit regulation in the two systems might be somewhat
different. Nevertheless, this amount of CNGA3 was sufficient
for a nearly complete functional rescue. This finding is con-
sistent with the recessive nature of the channelopathies
where one allele of the gene is sufficient to maintain a
normal channel and hence, normal cone function.
The improvement in retinal function in treated Cngb32/2
mice was manifested as a long-term recovery of cone ERG
responses, with the therapeutic effect maintained for up to
9 months PI. Our best functional rescue was observed in
animals treated at P15 and P30. Similar levels of functional
rescue reported in this study have only been shown previously
in Gnat22/2 mice treated at P23–29 with an AAV2/5 vector
carrying a mouse Gnat2 cDNA, where near wild-type level
recovery was achieved (22). However, this was achieved by
using a mouse, not a human, transgene. The degree of rescue
was dependent upon the age at which animals received treat-
ment: treatments performed at P15 and P30 led to a near
Figure 8. Gene therapy improves cone survival in Cngb32/2 mice. Injections were performed at P15 and eyes were collected at 60 days post-injection for PNA
lectin cytochemistry and analyses of cone-specific protein expression. (A) PNA labeling and cone-opsin staining in the treated Cngb32/2 eyes, compared with
the untreated control eyes. Retinal sections were analyzed for: (a) PNA lectin staining, (b) M-opsin and (c) S-opsin immunostaining. Shown are representative
images of the analysis from 4 to 6 mice/group and correlative quantitative results. OS, outer segment; ONL, outer nuclear layer; INL, inner nuclear layer, GCL,
ganglion cell layer. Scale bar: 50 mm. Quantitative results were obtained from 14 to 18 retinal sections prepared from four mice in each group. Unpaired Stu-
dent’s t-test was used for determination of the significance (P , 0.01). (B) Expression of M-opsin, S-opsin, CAR and GNAT2 in the injected-eyes analyzed by
western blot analysis. Retinal membrane preparations were resolved by 10% SDS–PAGE, followed by immunoblotting using antibodies against the respective
proteins. Shown are representative images of the analysis from 6 to 8 mice/group.
3168 Human Molecular Genetics, 2011, Vol. 20, No. 16
complete restoration of photopic ERG responses, while treat-
ment performed at P90 and P180 restored the ERG response
to 70% of the wild-type level. The reduced effectiveness
observed at later ages is likely related to the progression of
cone degeneration in older Cngb32/2 mice. Our data suggest
that treatment at a young age is likely to result in a complete
rescue. However, the effectiveness of therapy observed in
following treatment of oldermice suggests that there is potential
for achieving a substantial degree of therapeutic efficacy even
for adult patients.
Restored visual acuity in the treated Cngb32/2 mice pro-
vided further evidence of rescued cone-mediated visual func-
tion. The optokinetic reflex permits assessment of visual
acuity and contrast sensitivity. Visual acuity is a composite
function of cone responses plus inner retinal cell and central
visual pathway activities. The successful restoration of
visual acuity in the treated Cngb32/2 mice suggests that the
inner retinal function and the visual pathways involved
remain intact in Cngb32/2 mice, at least in young animals,
and are able to effectively process the input from the recov-
ered cones. It has been shown in mice and squirrel monkeys
that visual cortex becomes altered in response to changes in
peripheral inputs and that the inner retinal cells and central
visual pathways are able to adjust to incorporate an additional
cone class (24,43). Studies in achromatopsia patients have also
revealed changes in cortical pathways (44). Importantly, we
found in this study that in the Cngb32/2 mouse model there
is some plasticity. Improvement in visual acuity, however,
appears to be limited to animals treated at an early age: no
improvement in visual acuity was observed in the animals
treated at P180. Thus, although good retinal function, as
assessed by ERG, can be restored after treatment at all ages
and the effectiveness of therapy observed in following treat-
ment of older mice suggests there is potential to treat adult
patients, the lack of treatment effect on the visual acuity in
the older treated group indicates that an optimal therapeutic
window does exist. Without input from photoreceptors for a
certain period of time, the inner retina and central visual path-
ways may permanently lose their ability to reorganize in order
to effectively process the input from the recovered cones.
Although previous studies had suggested that achromatopsia
is a stationary disorder, recent studies using spectral-domain
optical coherence tomography measurements of CNGA3,
CNGB3 and PDE6C patients showed a correlation between
age and retinal thickness, suggesting that intervention should
occur within the first decade (45–47). Although it is imposs-
ible to equate the treatment window found in the mouse
model to humans, it is important to keep in mind for future
clinical trials that despite the relatively stationary nature of
CNGB3-related dystrophies, an optimal window for treatment
is likely to exist.
Cngb32/2 mice develop early onset, slow progression of
cone degeneration (30). Here, we showed that CNGB3 trans-
gene supplementation effectively reduced and potentially pre-
vented cone degeneration. The improved cone survival in the
treated Cngb32/2 eyes was shown by the improvement in
cone density, expression of cone proteins and improved struc-
ture of COSs. This was seen not only in mice treated at a
younger age (P15 days) but also in mice treated at a later
age (P90 days). Mice that were injected at P90 days and eval-
uated at 2 months PI also showed an increased cone density as
evaluated by cone opsin labeling and PNA staining (data not
shown). Hence, within a certain age range, supplementation
of CNGB3 transgene can ameliorate cone survival. This is in
line with the character of slow progression of cone degener-
ation in CNGB3 deficiency. The mechanism of cone death
resulting from CNG channel deficiency is not yet known and
Figure 9. Reduced cone-opsin mis-localization in Cngb32/2 mice following
gene therapy. The injections were performed at P6 and eyes were collected
at P16 for M-opsin labeling. (A) Shown are representative images of the analy-
sis from 4 to 6 mice/group for (a) wild-type, (b) treated and (c) untreated eyes,
with higher magnification images alongside (a′, b′, c′). OS, outer segment;
ONL, outer nuclear layer; and INL, inner nuclear layer. Scale bar: (a)
50 mm, (a′) 25 mm. (B) Quantitative analysis of the fluorescence intensities
of M-opsin labeling in the OS, ONL and OPL regions. Data represent
mean+SEM and results were obtained from 12 to 14 retinal sections pre-
pared from four mice in each group. Unpaired Student’s t-test was used for
determination of the significance (P , 0.01).
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may be due to multiple mechanisms. It may be attributed to a
decrease or loss of functional channels and subsequent impair-
ment or loss of cone phototransduction altogether. The trigger-
ing factors that link phototransduction deficiency with cone
death remain to be identified. Cone degeneration in
Cngb32/2 mice might also be associated with a potential
role of CNGB3 in outer segment morphogenesis and
maintenance of outer segment integrity, similar to its rod
counterpart CNGB1 (the rod CNG channel B subunit),
which has been shown to play a role in the morphogenesis
of rod outer segment discs (48). Our previous work showing
outer segment disorganization in cones of Cngb32/2 mice
(31) favors this view. In addition, the early onset cone
degeneration in Cngb32/2 mice might also be related to
impaired trafficking/mis-localization of cone opsins, which is
profound in developing and young mice; mis-localization
of opsin has been correlated with cellular stress and apopto-
sis (49,50).
In summary, subretinal injection of an rAAV2/8 vector car-
rying human CNGB3 driven by a human CAR promoter
restored cone function and survival in Cngb32/2 mice and
improved visual function. As mutations in the CNGB3 gene
are the most prevalent cause for achromatopsia, this study
provides proof of concept for a potentially very effective
therapy for the major subset of patients with this devastating
disorder.
MATERIALS AND METHODS
Animals, antibodies and other materials
Cngb32/2 mouse line (on C57BL/6N background) was gener-
ated by targeting deletion (Deltagen Inc., San Mateo, CA) as
described previously (31). Wild-type mice (C57BL/6) were
purchased from Charles River Laboratories (Wilmington,
MA, USA) or Harlan Laboratories (Blackthorn, UK). All
mice were maintained under cyclic light (12 h light-dark) con-
ditions; cage illumination was 7 foot-candles during the
light cycle. All experiments were approved by the local Insti-
tutional Animal Care and Use Committees (Oklahoma City,
USA; UCL, London, UK) and conformed to the guidelines
on the care and use of animals adopted by the Society for
Neuroscience and the Association for Research in Vision
and Ophthalmology (Rockville, MD).
The rabbit polyclonal antibodies against mouse CNGA3 and
mouse CNGB3 were generated and characterized as described
Figure 10. Preservation of cone structure in treated Cngb32/2 mice. The treatment was performed at P15 and eyes were collected at 60 days post-injection and
processed for transmission EM analysis. Shown are representative images taken from untreated (A and C) and treated (B and D) Cngb32/2 eyes. COS, cone
outer segment; ROS, rod outer segment. Asterisk (∗) denotes areas of disintegrated COS, containing undefined matrix material bordered by the COS plasma
membrane. Scale bar: 0.5 mm.
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previously (31,51). Rabbit polyclonal antibody against mouse
S-opsin was provided by Dr Muna Naash (University of Okla-
homa Health Sciences Center, Oklahoma City, OK). Affinity
purified polyclonal antibodies against mouse M-opsin and
cone arrestin were provided by Dr Cheryl Craft (University of
Southern California Keck School of Medicine, Los Angeles,
CA). Rabbit polyclonal antibody against GNAT2 was obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Mono-
clonal anti-actin antibody was purchased from Abcam, Inc.
(Cambridge, MA). Secondary, horseradish peroxidase
(HRP)-conjugated anti-rabbit or anti-mouse antibodies were
purchased from Kirkegaard & Perry Laboratories Inc.
(Gaithersburg, MD). All other chemicals were purchased from
Sigma-Aldrich (St Louis, MO), Bio-Rad Laboratories (Her-
cules, CA) or Invitrogen (Carlsbad, CA).
Construction and production of rAAV2/8.hCAR.hCNGB3
Human CNGB3 cDNA was a kind gift from Dr Hisao Ueyama
(Shiga University of Medial Science, Shiga, Japan) and was
cloned into a pD10 vector containing the hCAR (52). The
human CNGB3 gene was inserted in between the hCAR pro-
moter and the SV40 polyadenylation site to generate the con-
struct pD10_hCAR_hCNGB3. The construct was then
sequenced to verify that no spurious mutations had been incor-
porated during cloning.
Recombinant AAV2/8 serotype was produced through a
previously described tripartite transfection method (53).
AAV8 packaging, helper (pHGTI-adeno1) and pD10_h
CAR_hCNGB3 plasmids were transfected into 293T cells
with polyethylenimine (PEI; Polysciences, Inc., Eppelheim,
Germany) and left for 24 h. The cells were harvested 2 days
after transfection and treated with Benzonase (Sigma Aldrich,
Dorset, UK) after repeated freeze–thaw cycles to release the
vector. Virus preparation was cleared of cellular debris by mul-
tiple centrifugation steps followed by previously described puri-
fication using ion exchange chromatography (54). The virus
preparation was then concentrated in a Vivaspin 4 concentrator
(10 kDa, Sartorius StedimBiotech, Fisher Scientific, Loughbor-
ouh, UK) to the desired final volume. Viral genome titer was
determined using dot-blot analysis of purified virus preparations
and plasmid controls of known concentrations. The AAV2/
8_hCAR_hCNGB3 virus used in this study had a titer of 2 ×
1012 viral genomes/ml.
Subretinal injections
All procedures on animals were approved by the local UCL
Institute of Ophthalmology Ethics Committee and licensed
by the United Kingdom Home Office. Treated animals were
divided into five different groups according to the age at injec-
tion and subretinal injections of the viral vector were per-
formed on post-natal day (P) 6, P15, P30, P90 and P180 in
either the right or left eye (randomly selected) of Cngb32/2
mice. The contralateral eye was left as an untreated internal
control. Double injections were performed per eye, targeting
superior and inferior hemispheres of the retina, as previously
described (20). The volume of each injection was determined
according to age and eye size of the treated animal as follows:
1.5 ml each for animals injected at P6 and P15 and 2 ml
each for animals injected at P30, P90 and P180. Total viral
particles delivered per eye were 8 × 109 (P30, P90 and
P180) or 6 × 109 (P6 and P15).
Electroretinographic recordings and analysis
ERGs were recorded from both eyes of injected Cngb32/2
mice and age-matched wild-type controls on a monthly basis
interval starting at 30 days PI with a follow-up of a
minimum of 6 months. Un-injected eyes of treated animals
were designated as untreated controls. All animals were dark
adapted overnight prior to ERG recordings. The animals
were prepared for ERG recordings as described previously
(20). ERGs were recorded using commercially available
equipment (Espion E2, Diagnosys LLC, MA, USA). Bandpass
filter cut-off frequencies were 0.312 Hz for the low and
1000 Hz for the hig- frequency cut-off. Scotopic recordings
were obtained from dark-adapted animals at the following
increasing light intensities: 0.003, 0.007, 0.03 and 0.5 cd.s/
m2. The recordings consisted of 15 responses per intensity
with 10 s dark adaptation interval between each. Final
response was averaged for each intensity. Photopic recordings
were performed following 10 min light adaptation intervals on
a background light intensity of 20 cd/m2, which was also used
as the background light for the duration of photopic flash and
flicker recordings. Photopic flash recordings consisted of the
average of 25 responses for each intensity with a 60 s light
adaptation interval between each step. Light intensities used
were 0.1, 1, 3, 5, 10 and 20 cd.s/m2. Photopic flicker record-
ings consisted of 25 flashes per frequency for 0.5, 2, 5, 10,
15 and 30 Hz. Scotopic b-wave amplitudes were analyzed at
a light intensity of 0.007 cd.s/m2 and photopic at 10 cd.s/m2.
Statistical analysis
Two-way ANOVA for repeated measures with Bonferroni
post hoc tests and both paired and unpaired Student’s t-tests
were used to statistically evaluate data. The number of
animals for each group was as follows: injected at P6 group,
n ¼ 5; P15 group, n ¼ 16; P30 group, n ¼ 11; P90 group,
n ¼ 9; P180 group, n ¼ 6; wild-type group, n. 5. Statistical
analyses were performed using GraphPad Prismw version
5.01 for Windows (GraphPad Software, San Diego, CA,
USA).
Eye preparation, immunohistochemistry and confocal
microscopy
Mouse retinal sections were prepared for immunohistochem-
ical analysis as described previously (55,56). Briefly, mouse
eyes were enucleated and fixed in 4% formaldehyde in 0.1 M
sodium phosphate buffer, pH 7.4, at 48C overnight. The
superior portion of the cornea was marked for orientation
prior to enucleation. Fixed eyes were then transferred to
PBS or 0.1 M sodium phosphate buffer, pH 7.4, containing
0.02% sodium azide, for storage until processing. Tissue sec-
tions were prepared using either a Leica microtome (for paraf-
fin sections, 5 mm thickness) or a Leica cryostat (for frozen
sections, 10 mm thickness), respectively.
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Immunohistochemical labeling was performed as described
previously (31). Briefly, retinal sections were blocked with
PBS containing 5% BSA and 0.5% Triton-X 100 for 1 h at
room temperature. Primary antibody incubation (anti-CNGB3,
1:200; anti-CNGA3, 1:200; anti-M-opsin, 1:500; and
anti-S-opsin, 1:500) was performed at room temperature for
2 h. Following Alexa- or FITC-conjugated secondary antibody
incubation and rinses, slides were mounted and cover-slipped.
The PNA histochemistry was performed using biotinylated
PNA (Vector Laboratories, Burlingame, CA) (1:50) and
streptavidin-FITC (Sigma-Aldrich, St Louis, MO). The fluor-
escent signals were visualized and images were captured
using an Olympus AX70 fluorescence microscope (Olympus
Corp., Center Valley, PA) with the QCapturew imaging soft-
ware (QImaging Corp., Surrey, BC, Canada) and an
Olympus IX81-FV500 confocal laser scanning microscope
(Olympus, Melville, NY) (using excitation wavelengths of
543 nm for Alexa and 488 nm for FITC) with the FluoVieww
imaging software (Olympus, Melville, NY). Fluorescent label-
ing intensities of different regions of the retinal sections [outer
segment (OS), ONL and OPL] were analyzed using the
intensity mapping feature of the software, as described
previously (30).
Retinal membrane preparation, SDS–PAGE and western
blot analysis
Protein SDS–PAGE and western blotting were performed as
described previously (31). Briefly, retinas were homogenized
in homogenization buffer (10 mM Tris–HCl, pH 7.4, 1 mM
EDTA, 200 mM sucrose, 1 mM phenylmethylsulfonyl
fluoride) and the nuclei and cell debris were removed from
the homogenate by centrifugation at 1000g for 10 min at
48C. The resulting supernatant was centrifuged at 16 000g
for 30 min at 48C, and the resultant membrane
pellets were resuspended in buffer and used for western
blot analysis.
The retinal membrane proteins were subjected to
SDS–PAGE and transferred onto polyvinylidene diflouride
membranes. Following 1 h blocking in 5% non-fat milk at
room temperature, blots were incubated with primary anti-
bodies at appropriate dilution ratios (anti-M-opsin, 1:2,000;
anti-GNAT2, 1:500; anti-CAR, 1:2000; and anti-actin,
1:5000) overnight at 48C. After 3 × 10 min washings with
Tris-buffered saline with 0.1% Tween 20, the blots were incu-
bated with HRP-conjugated secondary antibodies (1:5,000 for
anti-actin and 1:25 000 for other antibodies) for 1 h at room
temperature. SuperSignalwWest Dura Extended Duration che-
miluminescent substrate (Pierce, Rockford, IL) was used to
detect binding of the primary antibodies to their cognate anti-
gens. Images were captured using a Kodak Imaging Station
(4000 R) (Molecular Imaging, New Haven, CT) and densito-
metry quantification was performed using the Kodak Molecu-
lar Imaging software.
RNA isolation and qRT–PCR
Total RNA was isolated from mouse retina using Trizol
reagent (Invitrogen, Carlsbad, CA). Two micrograms of total
RNA was reverse-transcribed using an oligo-dT primer and
SuperScript III reverse transcriptase (Invitrogen, Carlsbad,
CA) as per the manufacturer’s instructions. Control assays
without addition of transcriptase were included and the
products were used in the subsequent qRT–PCR as negative
controls.
qRT–PCR was performed to detect mRNA levels of mouse
Cnga3, human CNGB3 and HPRT-1. Primers were designed
to generate amplicons of 180–300 bp using Primer3 soft-
ware (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.
cgi). Primers for all genes were designed to span introns to
avoid amplification from genomic DNA and are shown in
Table 1. The assays were performed on each cDNA sample
using a real-time PCR detection system (iCycler; Bio-Rad
Laboratories, Hercules, CA). A relative gene expression
value △cT was calculated against HPRT-1 (gene cT 2
HPRT-1 cT) for each cDNA sample as described previously
(57). Disassociation curve analysis and agarose gel electro-
phoresis were performed on all PCR products to confirm
the proper amplification. The assays were repeated with
retinas from at least six animals for each group.
Transmission electron microscopy
Mouse eye samples were prepared for EM as described
previously (55,56). Tissue sections were obtained with a
Reichert–Jung Ultracut E microtome using a diamond knife.
Thin (600–800 A˚) sections were collected on copper 75/300
mesh grids for conventional EM analysis and stained with 2%
(w/v) uranyl acetate and Reynolds’ lead citrate. Sections were
viewed with a JEOL 100CX electron microscope at an accel-
erating voltage of 60 keV and digitized images were collected
and stored on a computer for subsequent viewing and analysis.
Evaluation of visual acuity by optomotor testing
Contrast sensitivities and visual acuities of treated and
untreated eyes were measured by observing the optomotor
responses of mice to rotating sinusoidal gratings (OptoMo-
try#, Cerebral Mechanics http://www.cerebralmechanics.
com/CerebralMechanics_Inc./OptoMotry.html) (58,59). The
protocol used yields independent measures of the acuities of
right and left eyes based on the unequal sensitivities of the
Table 1. Primers used in this study
Gene symbol Forward primer Reverse primers
Hprt GCAAACTTTGCTTTCCCTGG CAAGGGCATATCCAACAACA
hCNGB3 AAGTTCTTGGAGGCCCTGAT GGTTGCTTCTGCGGTCTTAG
mCNGA3 TGCACGACTCTCCCGGAAGTA ACCGGATAACCCGAGTCTCCA
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two eyes to pattern rotation: right and left eyes are most sen-
sitive to counter-clockwise and clockwise rotations, respect-
ively (58,59). A double-blind two-alternative forced choice
procedure was employed, in which the observer was ‘blind’
to the direction of pattern rotation, to whether it was a
treated or age-matched wild-type control animal and to
which eye received the AAV8/2_hCAR_hCNGB3 virus injec-
tion. Briefly, each mouse was placed on a pedestal located in
the centre of four inward facing LCD computer monitors
screens and was observed by an overhead infrared video
camera with infrared light source (Fig. 7A). Once the mouse
became accustomed to the pedestal, a 7s trial was initiated
by presenting the mouse with the sinusoidal pattern rotating
either clockwise or counter-clockwise as determined randomly
by the OptoMotry# software. The observer selected the direc-
tion of pattern rotation based on the animal’s optomotor
response and the monitors returned to 50% gray until the
next trial. Acuity was defined as the highest spatial frequency
(at 100% contrast) yielding a threshold response, and contrast
sensitivity was defined as 100 divided by the lowest percent
contrast yielding a threshold response. For photopic acuity,
animals were light adapted (.60 log cd/m2) for 30 min prior
to testing and the initial stimulus was a 0.200 cycles/degree
sinusoidal pattern with a fixed 100% contrast. For photopic
contrast sensitivity measurements, the initial pattern was pre-
sented at 100% contrast, with a fixed spatial frequency of
0.128 cycles/degree. Visual acuity and contrast sensitivity
were measured under photopic conditions (62 log cd/m2).
Visual acuities and contrast sensitivities were measured for
both eyes of each mouse at least three times on independent
days. Age-matched wild-type mice were tested alongside.
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